Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Polymyalgia Rheumatica
- Enrollment Status: Closed
- Protocol: CAIN457C22301+Extension
- Drug: COSENTYX® (secukinumab)
- Sponsor: Novartis
- Description: Novartis Pharmaceutical Trial entitled: A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR) Protocol No.: CAIN457C22301
University of Michigan Dermatology Research-Ann Arbor
Primary Coordinator Lisa Pilley, PA-C 734-936-4075
- Indication: Psoriasis and Psoriatic Arthritis
- Enrollment Status: Open
- Protocol: PS0039 “Be Unique”
- Drug: bimekizumab
- Sponsor: UCB
- Description: A Phase 3b Exploratory Multicenter Open-Label Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis With and Without Psoriatic Arthritis.
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Psoriatic Arthritis
- Enrollment Status: Open
- Protocol: PA0016 “Be Bold”
- Drug: Zasocitinib
- Sponsor: Takeda
- Description: A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Psoriatic Arthritis
- Enrollment Status: Open
- Protocol: TAK279PsA3001
- Drug: Bimekizumab
- Sponsor: UCB Pharma
- Description: PA0016- A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Psoriatic Arthritis
- Enrollment Status: Open
- Protocol: CNTO1959PSA4002-STAR
- Drug: Guselkumab
- Sponsor: Janssen
- Description: A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease